BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Janto K, Prichard JR, Pusalavidyasagar S. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. J Clin Sleep Med 2018;14:1399-408. [PMID: 30092886 DOI: 10.5664/jcsm.7282] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Liu J, Han J, Izawa K, Sato T, White S, Meanwell NA, Soloshonok VA. Cyclic tailor-made amino acids in the design of modern pharmaceuticals. Eur J Med Chem 2020;208:112736. [PMID: 32966895 DOI: 10.1016/j.ejmech.2020.112736] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
5 Toljan K, Homolak J. Circadian changes in Alzheimer's disease: Neurobiology, clinical problems, and therapeutic opportunities. Handb Clin Neurol 2021;179:285-300. [PMID: 34225969 DOI: 10.1016/B978-0-12-819975-6.00018-2] [Reference Citation Analysis]
6 Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. Lancet 2021;397:1577-90. [PMID: 33667416 DOI: 10.1016/S0140-6736(20)32205-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 39.0] [Reference Citation Analysis]
7 Kakizaki M, Tsuneoka Y, Takase K, Kim SJ, Choi J, Ikkyu A, Abe M, Sakimura K, Yanagisawa M, Funato H. Differential Roles of Each Orexin Receptor Signaling in Obesity. iScience 2019;20:1-13. [PMID: 31546102 DOI: 10.1016/j.isci.2019.09.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
8 Subramanian S, Ravichandran M. Orexin receptors: Targets and applications. Fundam Clin Pharmacol 2021. [PMID: 34464995 DOI: 10.1111/fcp.12723] [Reference Citation Analysis]
9 Besterman AD, Jeste SS. Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review. Eur Child Adolesc Psychiatry 2021. [PMID: 34611728 DOI: 10.1007/s00787-021-01883-7] [Reference Citation Analysis]
10 Mehr JB, Mitchison D, Bowrey HE, James MH. Sleep dysregulation in binge eating disorder and "food addiction": the orexin (hypocretin) system as a potential neurobiological link. Neuropsychopharmacology 2021. [PMID: 34145404 DOI: 10.1038/s41386-021-01052-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Brotschi C, Roch C, Gatfield J, Treiber A, Williams JT, Sifferlen T, Heidmann B, Jenck F, Bolli MH, Boss C. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep‐Promoting Properties in Rats. ChemMedChem 2019;14:1257-70. [DOI: 10.1002/cmdc.201900242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opin Investig Drugs 2019;28:951-65. [PMID: 31614096 DOI: 10.1080/13543784.2019.1681398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
13 Uchiyama M, Kambe D, Imadera Y, Kajiyama Y, Ogo H, Uchimura N. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study. Psychopharmacology (Berl) 2022. [PMID: 35296912 DOI: 10.1007/s00213-022-06089-6] [Reference Citation Analysis]
14 Vringer M, Kornum BR. Emerging therapeutic targets for narcolepsy. Expert Opin Ther Targets 2021;:1-14. [PMID: 34402358 DOI: 10.1080/14728222.2021.1969361] [Reference Citation Analysis]
15 Cable J, Holtzman DM, Hyman BT, Tansey MG, Colonna M, Kellis M, Brinton RD, Albert M, Wellington CL, Sisodia SS, Tanzi RE. Alternatives to amyloid for Alzheimer's disease therapies-a symposium report. Ann N Y Acad Sci 2020;1475:3-14. [PMID: 32472577 DOI: 10.1111/nyas.14371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Seigneur E, de Lecea L. Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery 2020;8:100070. [DOI: 10.1016/j.medidd.2020.100070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Alves M, Macedo IM, Távora C, Silva JF, Fonseca T. Sleep Disturbances Management in Elderly Hospitalized Patients. J Pharm Pract 2021;:8971900211053287. [PMID: 34686086 DOI: 10.1177/08971900211053287] [Reference Citation Analysis]
18 Mohammadi S, Dolatshahi M, Zare-shahabadi A, Rahmani F. Untangling narcolepsy and diabetes: Pathomechanisms with eyes on therapeutic options. Brain Research 2019;1718:212-22. [DOI: 10.1016/j.brainres.2019.04.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
19 Lalovic B, Majid O, Aluri J, Landry I, Moline M, Hussein Z. Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder. J Clin Pharmacol 2020;60:1642-54. [PMID: 32666570 DOI: 10.1002/jcph.1683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
20 Berro LF, Moreira-Junior EDC, Rowlett JK. The dual orexin receptor antagonist almorexant blocks the sleep-disrupting and daytime stimulant effects of methamphetamine in rhesus monkeys. Drug Alcohol Depend 2021;227:108930. [PMID: 34358767 DOI: 10.1016/j.drugalcdep.2021.108930] [Reference Citation Analysis]
21 Zammit G, Krystal A. Evaluating lemborexant for the treatment of insomnia. Expert Opin Pharmacother 2021;22:1235-43. [PMID: 33711243 DOI: 10.1080/14656566.2021.1902987] [Reference Citation Analysis]
22 Porwal A, Yadav YC, Pathak K, Yadav R. An Update on Assessment, Therapeutic Management, and Patents on Insomnia. Biomed Res Int 2021;2021:6068952. [PMID: 34708126 DOI: 10.1155/2021/6068952] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Costa A, Monti J, Torterolo P. Hypocretin (orexin) immunoreactivity in the feline midbrain: Relevance for the generation of wakefulness. J Chem Neuroanat 2020;105:101769. [PMID: 32145304 DOI: 10.1016/j.jchemneu.2020.101769] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Carter SG, Eckert DJ. Effects of hypnotics on obstructive sleep apnea endotypes and severity: Novel insights into pathophysiology and treatment. Sleep Med Rev 2021;58:101492. [PMID: 33965721 DOI: 10.1016/j.smrv.2021.101492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
26 Benca R, Herring WJ, Khandker R, Qureshi Z. Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer's Disease: A Structured Literature Review. J Alzheimers Dis 2022. [PMID: 35001893 DOI: 10.3233/JAD-215324] [Reference Citation Analysis]